tru Independence LLC increases stake in Johnson & Johnson (NYSE:JNJ)

tru Independence LLC boosted its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.8% in the second quarter, Holdings Channel.com reports. The firm owned 26,683 shares of the company’s stock after purchasing an additional 216 shares during the quarter. tru Independence LLC’s holdings in Johnson & Johnson were worth $3,900,000 as of its most recent SEC filing.

Other hedge funds have recently modified their positions in the company. Citizens & Northern Corp boosted its position in Johnson & Johnson by 3.5% in the second quarter. Citizens & Northern Corp now owns 1,884 shares of the company’s stock valued at $275,000 after acquiring an additional 63 shares in the last quarter. Carolinas Wealth Consulting LLC boosted its position in Johnson & Johnson by 0.4% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock valued at $2,643,000 after acquiring an additional 64 shares in the the last quarter. Epic Trust Investment Advisors LLC grew its position in Johnson & Johnson by 3.6% during the 2nd quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock valued at $268,000 after acquiring an additional 64 shares in the last quarter. Verity Asset Management Inc. boosted its position in Johnson & Johnson by 2.0% during the 4th quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock valued at $512,000 after acquiring an additional 65 shares during the last quarter. Finally, Outfitter Financial LLC raised its position in Johnson & Johnson by 0.4% during the 2nd quarter. Outfitter Financial LLC now owns 16,632 shares of the company’s stock valued at $2,431,000 after purchasing an additional 65 shares in the last quarter. 69.55% of the shares are currently held by hedge funds and other institutional investors.

Insider buying and selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.16% of the company’s shares.

Johnson & Johnson price performance

Shares of NYSE JNJ opened at $166.61 on Tuesday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The firm has a market cap of $401.07 billion, a P/E ratio of 10.39, a PEG ratio of 2.71 and a beta of 0.53. The company has a 50-day moving average of $157.98 and a 200-day moving average of $153.81. The company has a quick ratio of 0.85, a current ratio of 1.07, and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.80 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27. This represents a dividend of $4.96 on an annualized basis and a yield of 2.98%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analysts on Wall Street are forecasting an increase

Several research firms have weighed in on JNJ. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $160.00 to $150.00 in a research report on Tuesday , July 23. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. TD Cowen decreased their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Finally, Goldman Sachs Group dropped their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th . Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Moderate Buy” and a consensus price target of $173.21, according to MarketBeat.com.

Check out the latest stock analysis on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Featured stories

Want to see what other hedge funds JNJ owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Free Report).

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.